Custom modified oligonucleotides that model oxidative lesions, alkylated bases, UV-induced damage, abasic-site intermediates and epigenetic oxidation states for BER, NER, MMR, mutagenesis and repair assay development.
Bio-Synthesis supports custom lesion-containing oligonucleotides for DNA damage and repair research, including oxidative stress models, alkylation damage, UV photolesions, abasic-site mimics and TET/BER-related cytosine oxidation analogs.
Bio-Synthesis offers a broad portfolio of DNA damage and repair oligonucleotide modifications including oxidative lesions such as 8-oxo-dG and 8-oxo-dA, alkylation damage models including O6-Me-dG and O4-Me-dT, UV-induced lesions such as CPD and cis-syn thymidine dimers, abasic-site mimics including dSpacer and Pyrrolidine, and cytosine oxidation analogs for TET-mediated DNA demethylation studies.
Our team can help with lesion selection, position and density, matched unmodified controls, duplex design, optional handles/spacers, purification, analytical QC and custom packaging for tubes, vials or plate-based repair assays.
DNA damage and repair oligonucleotides are more than modified sequences. Lesion position, opposing base, duplex architecture, pathway choice, controls and analytical verification all affect how the substrate behaves in repair assays.
Design note: For most DNA repair substrates, place the lesion away from the ends and include enough flanking sequence for enzyme recognition and assay readout.
Design note: BER and NER substrates often require different duplex architectures. Pathway choice should guide lesion placement before synthesis.
Design note: Controls should match sequence context as closely as possible so differences reflect lesion biology rather than sequence or duplex effects.
Design note: Analytical strategy should be selected before ordering if the construct contains labile, bulky or multiple specialty lesions.
Design note: Advanced lesion panels should include matched controls and may benefit from custom plate formatting, concentration normalization and expanded documentation.
Start with the pathway question first, then select the lesion type, sequence context, duplex format and readout method.
BER-focused designs typically use single-base lesions or AP-site analogs positioned within duplex oligos.
NER and UV-damage designs require helix-distorting lesions and sufficient flanking sequence for recognition.
Mutagenesis and mismatch models test mispairing, polymerase bypass and lesion-specific coding outcomes.
Sequence context and clustered lesions help test repair pathway choice, radiation damage models and lesion density effects.
Use the tabs to compare lesion classes, product options and common applications without forcing customers through a long product catalog.
Design note: 8-oxo lesions can increase mispairing. Place in duplex regions when measuring glycosylase specificity or polymerase bypass.
Design note: For polymerase bypass studies, place O6-Me-dG opposite C or T to probe miscoding behavior.
Design note: Include flanking sequence context where possible to support NER recognition and repair-readout interpretation.
Design note: Avoid placing AP-site mimics at termini; internal placement improves nuclease, ligase and incision readouts.
Design note: For enrichment or antibody validation, include matched unmodified controls and consider both strand contexts.
The same lesion can be used differently depending on whether the goal is enzyme kinetics, assay development, toxicology or therapeutic resistance research.
Mechanistic repair studies usually need one defined lesion, matched duplex controls and clear enzyme-readout compatibility.
Assay development benefits from positive controls, negative controls and lesion panels matched to the detection method.
Environmental and toxicology studies often require lesion panels to model oxidative, alkylation or UV-induced DNA damage.
Therapeutic resistance research uses lesion-containing oligos to study DNA damage response, repair pathway dependency and lesion bypass.
Successful DNA damage and repair assays depend on controlled lesion placement, duplex design, purification and analytical confirmation.
Define BER, NER, MMR, UV repair or mutagenesis readout.
Choose oxidized, alkylated, UV, AP-site or cytosine oxidation analog.
Review lesion position, density, strand context and control design.
Incorporate lesion phosphoramidites or specialty analogs.
Use HPLC/UPLC, PAGE or method-matched cleanup.
Release with identity, purity, concentration, CoA and packaging.
Lesion-containing oligos can be sensitive to sequence context, assay placement and purification method. Bio-Synthesis supports analytical strategies matched to construct complexity and research use.
QC packages may include chromatographic purity, mass identity, OD260 concentration, duplex support, custom packaging and optional documentation for transfer into regulated research workflows.
Purity assessment and method-matched chromatographic profile.
Mass identity confirmation where compatible with lesion chemistry and construct size.
Quantitation, normalization and formulation-ready concentration reporting.
Optional endotoxin, residuals, stability points, plate formatting and barcodes.
Internal placement, flanking sequence and opposing base considerations.
Lesion-free, competitor, opposite-strand and sequence-context controls.
Discovery µmol to larger supply, tubes, vials, plates, labels and barcodes.
DNA damage and repair oligonucleotides require controlled synthesis, purification and analytical release methods matched to lesion chemistry and assay use.
Bio-Synthesis supports lesion selection, synthesis, purification, analytical characterization, custom packaging and documentation for DNA damage and repair oligonucleotide programs.
Connect DNA damage repair assay design with the right Bio-Synthesis synthesis, modification and QC service.
→
Compare BER, NER, UV damage, mutagenesis and AP-site models.
Purification, LC-MS, analytical purity, concentration, labeling and documentation.
Use this section to support scientific credibility while keeping the page focused on lesion selection, synthesis, assay design and analytical verification.
Suggested page note: References are provided for scientific background. Final lesion oligo design should be evaluated within the sequence, lesion position, pathway, assay readout, purification method and QC requirements.
Trusted by biotech leaders worldwide for over 45+ years of delivering high quality, fast and scalable synthetic biology solutions.